Bisabolangelone isolated from Ostericum koreanum inhibits the production of inflammatory mediators by down-regulation of NF-kappaB and ERK MAP kinase activity in LPS-stimulated RAW264.7 cells.
Bisabolangelone, a sesquiterpene derivative, was isolated from the roots of Osterici Radix (Ostericum koreanum Maximowicz). In this study, the anti-inflammatory effect of bisabolangelone was investigated to address potential therapeutic effects in lipopolysaccharide (LPS)-stimulated mouse macrophage RAW 264.7 cells. Bisabolangelone significantly inhibited NO, PGE(2), and pro-inflammatory cytokines by suppressing the mRNA and protein expressions of iNOS and COX-2. Bisabolangelone also inhibited the productions of pro-inflammatory cytokines (TNF-alpha, IL-1beta and IL-6) by suppressing the cytokine mRNA and protein expressions. The molecular mechanism of bisabolangelone-mediated attenuation in RAW 264.7 cells has a close relationship to suppressing the translocation of nuclear factor-kappaB (NF-kappaB) p65 subunit into the nucleus and the phosphorylation of mitogen-activated protein kinases (MAPKs). These results indicate that bisabolangelone inhibits LPS-stimulated inflammation through the blocking of NF-kappaB and MAPK pathways in macrophages, and demonstrated that bisabolangelone possesses anti-inflammatory properties.
Jung
Hyo Won
HW
Oriental Medicine R&D Center, Dongguk University, Gyeongju 780-714, Republic of Korea.
Mahesh
Ramalingam
R
Park
Jun Hong
JH
Boo
Yong Chool
YC
Park
Kwon Moo
KM
Park
Yong-Ki
YK
D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000302:isolation & purification / Q000494:pharmacology*; D019661:Apiaceae / Q000737:chemistry*; D002460:Cell Line; D052246:Cyclooxygenase 2 Inhibitors / Q000627:therapeutic use; D016207:Cytokines / Q000037:antagonists & inhibitors; D015232:Dinoprostone / Q000037:antagonists & inhibitors; D015536:Down-Regulation / Q000187:drug effects; D048049:Extracellular Signal-Regulated MAP Kinases / Q000037:antagonists & inhibitors*; D007249:Inflammation / Q000188:drug therapy; D018836:Inflammation Mediators / Q000037:antagonists & inhibitors*; D008070:Lipopolysaccharides / Q000037:antagonists & inhibitors*; D008264:Macrophages / Q000187:drug effects; D051379:Mice; D016328:NF-kappa B / Q000037:antagonists & inhibitors*; D009569:Nitric Oxide / Q000037:antagonists & inhibitors; D010936:Plant Extracts / Q000302:isolation & purification; D018517:Plant Roots / Q000737:chemistry; D012717:Sesquiterpenes / Q000302:isolation & purification / Q000494:pharmacology*
D000894:Anti-Inflammatory Agents, Non-Steroidal; D052246:Cyclooxygenase 2 Inhibitors; D016207:Cytokines; D018836:Inflammation Mediators; D008070:Lipopolysaccharides; D016328:NF-kappa B; D010936:Plant Extracts; D012717:Sesquiterpenes; C455067:bisabolangelone; D009569:Nitric Oxide; D048049:Extracellular Signal-Regulated MAP Kinases; D015232:Dinoprostone